Showing results (101-110 of 159) with videos related to
Sort By:
Pageof 16
Journal of the American Academy of Dermatology|October 11, 2017
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsKenneth B Gordon, Keith A Betts, Murali Sundaram, et al.Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.Journal of the American Academy of Dermatology|May 17, 2016
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasisPeter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, et al.Dermatology and Therapy|August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation AnalysisApril W Armstrong, Peter Foley, Yan Liu, et al.Dermatology and Therapy|November 4, 2023
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative ReviewAndrew Blauvelt, Richard G Langley, Kenneth B Gordon, et al.Clinical Therapeutics|November 18, 2005
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experienceRichard G B Langley, Wayne P Carey, Elyse S Rafal, et al.International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.The Journal of Allergy and Clinical Immunology|April 1, 2014
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasisHoward Sofen, Stacy Smith, Robert T Matheson, et al.The Journal of Dermatology|October 22, 2019
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2Kristian Reich, Michael Song, Shu Li, et al.JAMA Dermatology|April 9, 2020
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical TrialAndrew Blauvelt, Craig L Leonardi, Melinda Gooderham, et al.Pageof 16